Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
基本信息
- 批准号:8867146
- 负责人:
- 金额:$ 28.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-30 至 2015-10-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAdverse effectsAffectAmericanAmerican Cancer SocietyAndrogen AntagonistsAndrogen ReceptorAndrogensAngelicaAngelica sinensis preparationAngiogenic FactorAnimal ModelAntibodiesAntineoplastic AgentsApoptosisAsiansAttentionBiological FactorsBiological MarkersBiological ModelsBotanicalsCell Culture TechniquesCell ProliferationCell physiologyCessation of lifeChemicalsChemopreventive AgentClinicalColon CarcinomaComplementary and alternative medicineComplexCytotoxic agentDataDevelopmentDrug KineticsEthanolFDA approvedFibroblast Growth Factor 2FractionationFutureGoalsGrowthHormonesHumanImmunodeficient MouseIn VitroIsomerismKnock-outKnowledgeKoreansLNCaPLungMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMediator of activation proteinMethodsModalityModelingMolecularMolecular TargetMusNatureNeoplasm MetastasisOrganOutcomePathway interactionsPatientsPharmaceutical ChemistryPharmaceutical PreparationsPharmacodynamicsPre-Clinical ModelPreventionPreventiveProstateProstate carcinomaProteomicsPublishingQuality ControlQuality of lifeRadiosurgeryRecurrenceRefractory DiseaseResearchResearch PersonnelRodentRoleSafetySiteSonSourceStagingStreamStructureSystems BiologyTargeted ResearchTestingTissuesToxic effectTranslatingTranslationsTumor AngiogenesisWarWorkXenograft Modelalcohol effectangiogenesisbasecancer chemopreventioncancer diagnosiscancer preventioncarcinogenesiscellular targetingchemotherapycomparative efficacycostdocetaxeldrug discoveryevidence basefightingin vivoindexinginnovationinsightmalemenmouse modelnovelpre-clinicalprostate cancer cellprostate cancer modelprostate cancer preventionprostate carcinogenesisresearch and developmentscreeningstatisticstooltranscriptomicstransgenic adenocarcinoma of mouse prostateunpublished works
项目摘要
DESCRIPTION (provided by applicant): Our long-term goal is to develop non-toxic, low-cost and efficacious herbal modalities from Korean Angelica gigas Nakai (AGN) for the prevention of prostate carcinogenesis and metastasis in men. We have shown in preclinical models significant prostate cancer growth-inhibitory and chemopreventive effects of AGN ethanol extracts without any observable toxicity to the host mice. Nevertheless, a lack of mechanistic knowledge of active chemicals and in vivo molecular targets is a significant roadblock to translating the preventive benefits to men. The objective for the current application is to generate mechanistic knowledge of (1) the active chemicals and (2) cellular and molecular targets in two independent and complementary prostate cancer models. We hypothesize that AGN extract exerts in vivo efficacy (a) mainly through pyranocoumarin compounds and their metabolite; (b) by affecting critical cellular processes and molecular targets, which can be effectively profiled through a systems-biology approach. We plan to test these hypotheses by pursuing three specific aims: Aim 1. Establish the chemical mediator role of the pyranocoumarins by comparing the efficacy of purified compounds with AGN extract and pyranocoumarin-knockout (KO) extract to inhibit human prostate cancer growth and metastasis in xenograft models in immunodeficient mice. Aim 2. Validate their mediator role for chemopreventive efficacy against primary carcinogenesis in the transgenic adenocarcinoma of mouse prostate (TRAMP) model by comparing them with AGN extract and KO extract. Aim 3. Determine key cellular indices and molecular biomarkers of in vivo efficacy including angiogenesis, apoptosis, cell proliferation and invasiveness by focused analyses and identify molecular targets with systems-biology approaches, using suitable tissues from the first two aims. The work proposed in Aims 1 and 2 is expected to critically assess the role of pyranocoumarins and metabolites as chemical mediators for the inhibitory efficacy of AGN extract against prostate primary carcinogenesis and metastasis, and establish their long-term safety profiles in mice models. Such results are expected to positively impact future focused R&D efforts and quality control for AGN herbal products. Aim 3 results are expected to identify candidate in vivo molecular targets and cellular processes. Better knowledge of the active chemicals and their molecular targets in model systems enables further mechanistic studies and rational planning for clinical translation in men. Furthermore, the efficacy and mechanisms are likely exportable to the prevention of cancers of other organ sites by AGN extracts. The research proposed is innovative, in our opinion, because it represents a substantial departure from the status quo for preclinical cancer chemoprevention research of single-agent/single-target approach. The comprehensive research with cutting- edge medicinal chemistry methods (e.g., knockout extract) and systems-biology tools (e.g., iTRAQ proteomics) can help moving herbal remedies toward evidence-based complementary and alternative medicine.
描述(由申请人提供):我们的长期目标是开发无毒、低成本且有效的韩国当归(AGN)草药,用于预防男性前列腺癌的发生和转移。我们在临床前模型中证明了 AGN 乙醇提取物具有显着的前列腺癌生长抑制和化学预防作用,且对宿主小鼠没有任何可观察到的毒性。然而,缺乏对活性化学物质和体内分子靶点的机械知识是将预防益处转化为男性的重大障碍。当前应用的目标是在两个独立且互补的前列腺癌模型中生成(1)活性化学物质和(2)细胞和分子靶标的机械知识。我们假设 AGN 提取物发挥体内功效 (a) 主要通过吡喃香豆素化合物及其代谢物; (b) 通过影响关键的细胞过程和分子靶标,可以通过系统生物学方法有效地分析这些过程和分子靶标。我们计划通过实现三个具体目标来测试这些假设: 目标 1. 通过比较纯化化合物与 AGN 提取物和吡喃香豆素敲除 (KO) 提取物抑制人类前列腺癌生长和转移的功效,确定吡喃香豆素的化学介导作用。免疫缺陷小鼠的异种移植模型。目标 2. 通过与 AGN 提取物和 KO 提取物进行比较,验证它们在转基因小鼠前列腺腺癌 (TRAMP) 模型中对原发性癌的化学预防功效的介导作用。目标 3. 通过集中分析确定体内功效的关键细胞指标和分子生物标志物,包括血管生成、细胞凋亡、细胞增殖和侵袭性,并使用前两个目标中的合适组织,通过系统生物学方法识别分子靶点。 目标 1 和 2 中提出的工作预计将严格评估吡喃香豆素及其代谢物作为化学介质对 AGN 提取物对前列腺原发性癌变和转移的抑制功效的作用,并在小鼠模型中建立其长期安全性。这些结果预计将对 AGN 草药产品未来的重点研发工作和质量控制产生积极影响。目标 3 的结果预计将确定候选的体内分子靶标和细胞过程。更好地了解模型系统中的活性化学物质及其分子靶标,可以进行进一步的机制研究和合理规划男性临床转化。此外,其功效和机制可能可用于通过 AGN 提取物预防其他器官部位的癌症。我们认为,所提出的研究具有创新性,因为它与单药/单靶点方法的临床前癌症化学预防研究现状有很大不同。利用尖端药物化学方法(例如,敲除提取物)和系统生物学工具(例如,iTRAQ 蛋白质组学)进行的综合研究可以帮助将草药疗法转向基于证据的补充和替代医学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JUNXUAN LU其他文献
JUNXUAN LU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JUNXUAN LU', 18)}}的其他基金
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
- 批准号:
9175121 - 财政年份:2015
- 资助金额:
$ 28.17万 - 项目类别:
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM
下一代硒预防前列腺癌
- 批准号:
8504056 - 财政年份:2013
- 资助金额:
$ 28.17万 - 项目类别:
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM
下一代硒预防前列腺癌
- 批准号:
9063529 - 财政年份:2013
- 资助金额:
$ 28.17万 - 项目类别:
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM
下一代硒预防前列腺癌
- 批准号:
8829786 - 财政年份:2013
- 资助金额:
$ 28.17万 - 项目类别:
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM
下一代硒预防前列腺癌
- 批准号:
8625728 - 财政年份:2013
- 资助金额:
$ 28.17万 - 项目类别:
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM
下一代硒预防前列腺癌
- 批准号:
9262164 - 财政年份:2013
- 资助金额:
$ 28.17万 - 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
- 批准号:
9044040 - 财政年份:2012
- 资助金额:
$ 28.17万 - 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
- 批准号:
8368398 - 财政年份:2012
- 资助金额:
$ 28.17万 - 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
- 批准号:
8547743 - 财政年份:2012
- 资助金额:
$ 28.17万 - 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
- 批准号:
8700324 - 财政年份:2012
- 资助金额:
$ 28.17万 - 项目类别:
相似国自然基金
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
D.formicigenerans菌通过调控FoxP3-Treg影响PD-1抑制剂所致免疫相关不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Evaluation of peripheral nerve stimulation as an alternative to radiofrequency ablation for facet joint pain
周围神经刺激替代射频消融治疗小关节疼痛的评估
- 批准号:
10734693 - 财政年份:2023
- 资助金额:
$ 28.17万 - 项目类别:
Perception of Dead Conspecifics modulates neural signaling and lifespan in Caenorhabditis elegans
对死亡同种的感知调节秀丽隐杆线虫的神经信号和寿命
- 批准号:
10828478 - 财政年份:2023
- 资助金额:
$ 28.17万 - 项目类别:
FGF21 as a mediator of RPE mitochondrial dysfunction
FGF21 作为 RPE 线粒体功能障碍的介质
- 批准号:
10586472 - 财政年份:2023
- 资助金额:
$ 28.17万 - 项目类别:
Development and Preclinical Evaluation of Nanoformulations in Liver Fibrotic Mice
肝纤维化小鼠纳米制剂的开发和临床前评价
- 批准号:
10639037 - 财政年份:2023
- 资助金额:
$ 28.17万 - 项目类别:
Sensory Mechanisms of Cadmium-Induced Behavioral Disorders Across Generations
镉引起的几代人行为障碍的感觉机制
- 批准号:
10747559 - 财政年份:2023
- 资助金额:
$ 28.17万 - 项目类别: